- Home
- COKE vs JAZZ Comparison
COKE vs JAZZ Comparison
Compare COKE & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COKE | JAZZ |
|---|---|---|
| Founded | 1902 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.4B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | COKE | JAZZ |
|---|---|---|
| Price | $153.52 | $168.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $207.19 |
| AVG Volume (30 Days) | 548.0K | ★ 1.1M |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 22.14 | N/A |
| EPS | ★ 7.03 | N/A |
| Revenue | ★ $7,070,308,000.00 | $4,157,832,999.00 |
| Revenue This Year | N/A | $6.00 |
| Revenue Next Year | N/A | $6.35 |
| P/E Ratio | $21.78 | ★ N/A |
| Revenue Growth | ★ 4.22 | 4.14 |
| 52 Week Low | $105.21 | $95.49 |
| 52 Week High | $169.49 | $182.99 |
Technical Indicators
Market Signals| Indicator | COKE | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 53.97 |
| Support Level | $147.28 | $165.01 |
| Resistance Level | $154.50 | $172.59 |
| Average True Range (ATR) | 3.49 | 5.96 |
| MACD | 0.17 | -0.14 |
| Stochastic Oscillator | 82.00 | 67.69 |
Price Performance
Historical ComparisonAbout COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.